A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes

Diabetic Medicine

Volumn 27, Issue 2, 2010, Pages 181-188

  Fogelfeld, L ^a   Dharmalingam, M ^b   Robling, K ^c   Jones, C ^c   Swanson, D ^d   Jacober, S ^c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b M S RAMAIAH MEDICAL COLLEGE   (India)

^c ELI LILLY AND COMPANY   (United States)

^d i3 Statprobe   (United States)

Author keywords

Body weight; Glucose variability; Hypoglycaemia; Insulin lispro protamine suspension; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN LISPRO; METFORMIN; PROTAMINE; SULFONYLUREA; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; LONG ACTING INSULIN;

ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DIARRHEA; DIET RESTRICTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; AGED; ANALOGS AND DERIVATIVES; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY;

AGED; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN LISPRO; INSULIN, LONG-ACTING; MALE; MIDDLE AGED;

EID: 76249125860     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02899.x     Document Type: Article

References (14)

1. Dornhorst A, Lüddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ et al. Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract 2008 62 : 659 665.
2. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care 2009 32 (Suppl. 1 S13 S61.
3. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005 28 : 2673 2679. (Pubitemid 43951158)
4. Hayes RP, Fitzgerald JT, Jacober SJ. Primary care physician beliefs about insulin initiation in patients with type 2 diabetes. Int J Clin Pract 2008 62 : 860 868.
5. Cefalu WT, Mathieu C, Davidson J, Freemantle N, Gough S, Canovatchel W. Patients' perceptions of subcutaneous insulin in the OPTIMIZE study: a multicenter follow-up study. Diabetes Technol Ther 2008 10 : 25 38.
6. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009 32 : 193 203.
7. Hompesch M, Ocheltree SM, Wondmagegnehu ET, Morrow LA, Kollmeier AP, Campaigne BN et al. Insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes: pharmacokinetics and pharmacodynamics of three basal insulin analogues. Curr Med Res Opin 2009 25 : 2679 2687.
8. Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A et al. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med 2008 149 : 531 539.
9. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1, Diagnosis and Classification of Diabetes Mellitus. Geneva : World Health Organization, 1999 : 1 59.
10. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006 29 : 1269 1274.
11. The DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 1991 90 : 450 459.
12. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008 51 : 408 416.
13. Johnson CK, Shimshi M. When a unit of insulin is not a unit: detemir dosing and insulin cost in type 2 diabetes mellitus. Insulin 2009 4 : 87 93.
14. Riddle MC. Starting and advancing insulin for type 2 diabetes: algorithms and individualized methods are both necessary. J Clin Endocrinol Metab 2008 93 : 372 374.